Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Garzotto

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient miceXi Zheng, Richard L Chang, Xiao-Xing Cui, et al.
Nutrition and Cancer|June 4, 2019
Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled TrialZhenzhen Zhang, Mark Garzotto, Edward W Davis, et al.
Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
European Urology|January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized StudyDaniel W Lin, Mei-Chiung Shih, William Aronson, et al.
The American Journal of Managed Care|January 17, 2018
Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assayJulie A Lynch, Megan P Rothney, Raoul R Salup, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerAmir Goldkorn, Benjamin Ely, David I Quinn, et al.
International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient miceXi Zheng, Richard L Chang, Xiao-Xing Cui, et al.
Nutrition and Cancer|June 4, 2019
Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled TrialZhenzhen Zhang, Mark Garzotto, Edward W Davis, et al.
Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
European Urology|January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized StudyDaniel W Lin, Mei-Chiung Shih, William Aronson, et al.
The American Journal of Managed Care|January 17, 2018
Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assayJulie A Lynch, Megan P Rothney, Raoul R Salup, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2014
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerAmir Goldkorn, Benjamin Ely, David I Quinn, et al.
International Journal of Cancer|September 16, 2014
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn, Benjamin Ely, Catherine M Tangen, et al.
Pageof 8